Audentes Therapeutics (BOLD) started trading on the Nasdaq on 19 July 16

• Headquarters: San Francisco, CA
• Founded: 2012
• audentestx.com

Audentes is one of the leaders in the nascent field of gene therapy, using an adeno-associated virus, or AAV, vector to carry a healthy copy of a gene into a cell. The viral vectors essentially are vehicles, modified so they aren't infectious but can slip past a cell's normal defenses to deliver the healthy gene.

Audentes sold 5 million shares at $15 apiece in its IPO. The $75 million raise will help Audentes fund clinical work it’s doing on rare diseases such as X-Linked myotubular myopathy, Crigler-Najjar Syndrome, and Pompe disease.

Description

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Key stats and ratios

	Q2 (Jun '17)	2016
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-58.78%	-45.98%
Return on average equity	-68.94%	-139.89%
Employees	97